Stemirna Therapeutics

Stemirna Therapeutics

Stemirna Therapeutics is an mRNA therapeutics and nanoparticle formulation company in China focused on treatments for cancer, infectious diseases and rare diseases.

Stemirna Therapeutics is an mRNA therapeutics and nanoparticle formulation company in China focused on treatments for cancer, infectious diseases and rare diseases. Stemirna Therapeutics was founded in the Zhangjiang Drug Valley of Shanghai, in 2016. Now it is located in the Jinqiao Pilot Free Trade Zone.

Stemirna has a candidate vaccine targeting the novel coronavirus, causing the illness COVID-19, which began animal testing in February 2020. The mRNA vaccine was co-developed by the Chinese Center for Disease Control and Prevention (CDC), Shanghai-based Tongji University School of Medicine and Stemirna.

Stemirna Therapeutics looks to utilize the full potential of RNA in order to create personalized vaccines for cancer, infectious diseases, protein defective diseases, and genetic diseases. Cures and solutions for morbid diseases to help save patients is the main goal for the company.

The company is interested in working directly with gene expression through messenger RNA, as the genetic information that is written into the nucleus of a cell produces mRNA. This is then translated to cytoplasm to produce proteins with various physiological functions.

Timeline

August 12, 2019
Stemirna Therapeutics raises a $14,164,305 series A round from Fanghua Investment, Zhangjiang Torch Venture Capital Co, Lapam Capital and Jiuyou Capital.
2016
Stemirna Therapeutics was founded by Dr. Hangwen Li.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Stemirna Therapeutics Series A round, August 2019
14,164,305
August 12, 2019
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.